Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – Research ...

Merck & Co has a lower P/E than the aggregate P/E of 26.97 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license agreement with United States-based Merck ...

March 25 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals ... as the company prepares to participate in ...

Takeda Pharmaceutical Trading Up 0.8 % Shares of Takeda Pharmaceutical stock opened at $15.15 on Friday. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15. ...

It is a cancer drug her company discovered—one that has made her the face of a rising pharmaceutical star ... has shown favorable results versus Merck’s $29.5-billion-a-year cancer treatment ...